Pranita D Tamma

About

Pranita D Tamma, MD, MHS, is a Professor of Pediatrics in the Department of Pediatrics at the University of Pennsylvania's Perelman School of Medicine. She is based at Johns Hopkins Hospital, The David M. Rubinstein Child Health Building, Baltimore, MD. Her educational background includes an MD from the State University of New York Downstate Medical School obtained in 2004, and a Master of Health Science (MHS) in Clinical Investigations from Johns Hopkins University School of Public Health in 2011. Her professional focus encompasses pediatric infectious diseases, with a particular emphasis on antimicrobial therapies and infection management. She has contributed extensively to clinical research and guidelines in infectious diseases, as evidenced by her numerous publications in the field.

Research topics

• Internal medicine
• Medicine
• Microbiology

Selected publications

• Infectious Diseases Society of America 2023 Guidance on the Treatment of Antimicrobial Resistant Gram-Negative Infections

  Clinical Infectious Diseases · 2023-07-18 · 675 citations

  articleOpen access1st author

  BACKGROUND: The Infectious Diseases Society of America (IDSA) is committed to providing up-to-date guidance on the treatment of antimicrobial-resistant infections. This guidance document focuses on infections caused by extended-spectrum β-lactamase producing Enterobacterales (ESBL-E), AmpC β-lactamase-producing Enterobacterales (AmpC-E), carbapenem-resistant Enterobacterales (CRE), Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa), carbapenem-resistant Acinetobacter b…

  PublisherOA PDFDOI

• Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase–Producing Enterobacterales, Carbapenem-Resistant<i>Acinetobacter baumannii</i>, and<i>Stenotrophomonas maltophilia</i>Infections

  Clinical Infectious Diseases · 2021-12-03 · 509 citations

  reviewOpen access1st authorCorresponding

  The Infectious Diseases Society of America (IDSA) is committed to providing up-to-date guidance on the treatment of antimicrobial-resistant infections. A previous guidance document focused on infections caused by extended-spectrum β-lactamase-producing Enterobacterales (ESBL-E), carbapenem-resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with difficult-to-treat resistance (DTR-P. aeruginosa). Here, guidance is provided for treating AmpC β-lactamase-producing Enterobacterales (AmpC-E)…

  PublisherOA PDFDOI

• Author response for "Cefiderocol under siege? Understanding the rise of NDM-mediated resistance"

  2025-05-19

  peer-review
  PublisherDOI

Recent grants

• The Use of MALDI TOF for the Rapid Detection of Carbapenemases from Clinical Isolates

  NIH · $734k · 2016–2020

• Modifiable Risk Factors for the Emergence of Resistance to Pseudomonas aeruginosa

  NIH · $479k · 2021–2024

• Identifying Optimal Antibiotic Treatment for Non-CTX-M-Producing ESBL Bloodstream Infections

  NIH · $450k · 2023–2026

Frequent coauthors

• Sara E. Cosgrove

  Agency for Healthcare Research and Quality

  332 shared

• Patricia J. Simner

  Johns Hopkins Hospital

  210 shared

• Aaron M. Milstone

  Johns Hopkins University

  169 shared

• Robert A. Bonomo

  University School

  97 shared

• Karen C. Carroll

  Johns Hopkins University

  87 shared

• Yehudit Bergman

  Johns Hopkins Medicine

  83 shared

• Jeffrey S. Gerber

  Children's Hospital of Philadelphia

  78 shared

• Sara C. Keller

  Johns Hopkins Medicine

  75 shared

Labs

• Pranita D Tamma LabPI

Similar researchers at Johns Hopkins University

• John Q. Trojanowskih-296
• Craig B. Thompsonh-277
• Daniel J Raderh-236